Even more encouraging, Myriad already has developed gene-based screening tests for other types of cancer.
The gene-based technique marks a new approach toward cancer screening, and specialists are watching closely.
At HGS seven gene-based drugs have entered trials, but most remain in the earlier stages of clinical testing.
In the long term gene-based tests could enhance treatment of most major diseases, including asthma, arthritis and even schizophrenia.
Scientists believe that between 5% and 15% of cancers are hereditary and are therefore detectable by gene-based diagnostic tests.
But gene-based health care is here and now in another form: molecular diagnostics.
The goal: a gene-based prognostic test, one that could predict years in advance which tumor will metastasize and kill you.
Regardless of our opinion about whether this is good or bad, ongoing discoveries will usher in a new age of gene-based products and services.
Rather than trying to predict which diagnostic tests and gene-based drugs will emerge and make money, what you can do is invest in the technology itself.
He predicts the company should benefit as doctors start demanding new gene-based diagnostic tests for their patients, such as new methods for genotyping the AIDS virus.
H3 was located by a research team led by Michael Jackson, Peterson's former colleague at Scripps, who deployed the La Jolla group a few years ago to find gene-based drugs.
Sir David expects that the company will put its first drug, one of a new type of gene-based drugs designed to combat specific cancer tumours, to clinical trial later this year.
San Francisco-based Gene Gibbs is also an arch air-miles strategist.
Most prominently, teenager Jesse Gelsinger died from multiple organ failure a few days after receiving a massive dose of virus-based gene therapy in a trial at the University of Pennsylvania.
It is working on better protein-based drugs, gene therapy, industrial enzymes, and ag-biotech.
But developing drugs from genes has turned out to be very difficult, and now companies like Myriad and Millennium have turned to buying potential drugs to tide them over until drugs based on their gene-finding technology can make it to market.
Drug firms like Pfizer, GlaxoSmithKline and Novartis have yet to realize a new generation of big-selling medicines based on gene research.
Drug firms like Pfizer (nyse: PFE - news - people ), GlaxoSmithKline (nyse: GSK - news - people ) and Novartis (nyse: NVS - news - people ) have yet to realize a new generation of big-selling medicines based on gene research.
Meanwhile, researchers at Biogen in Cambridge, Massachusetts and rivals at Seattle-based ZymoGenetics had discovered BLYS and its receptors by using other gene databases.
DNA-based test to complement their myoglobin work, following the success of other groups in using gene fragments in coprolites as windows into ancient diets.
应用推荐